Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term (74-month) efficacy and safety of ivosidenib and azacitidine in an elderly patient with mutated IDH1 acute myeloid leukemia: insights from a case report.

Postgraduate medicine - 1 May 2026

Wróbel Tomasz, Kalicińska Elzbieta

Abstract excerpt

INTRODUCTION: Older patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (IC) are more likely to have poor outcomes. Ivosidenib is a first-in-class, oral, targeted small-molecule inhibitor of mutated isocitrate dehydrogenase (mIDH1) approved for use with azacitidine, following the AGILE trial (NCT03173248), for the treatment of mIDH1 AML in patients who are unfit for IC. CASE...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Pyridines

Share to Treatment Outcome

Source

Identifiers

PMID: 42108620
DOI: 10.1080/00325481.2026.2668750

Genes

IDH1
RUNX1
U2AF1
ASXL1
DNMT3A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term (74-month) efficacy and safety of ivosidenib and azacitidine in an elderly patient with mutated IDH1 acute myeloid leukemia: insights from a case report.PMID 42108620Read ↗

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.Semantic proximity Read ↗

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Semantic proximity Read ↗

A narrative review of mutant isocitrate dehydrogenase AML in Japan based on experience with ivosidenib in AGILE.Semantic proximity Read ↗

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.Semantic proximity Read ↗

FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.Semantic proximity Read ↗

Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia.Semantic proximity Read ↗

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: a real-world studySemantic proximity Read ↗

Prognostic Implications and Therapeutic Landscape of IDH1-Mutated AML: An Updated Review of Evidence and Indian Perspective.Semantic proximity Read ↗

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.Semantic proximity Read ↗

Evaluating ivosidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Ivosidenib in acute myeloid leukemia.Semantic proximity Read ↗

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.